天津医药

天津医药 ›› 2020, Vol. 48 ›› Issue (6): 567-571.

• 综述 • 上一篇    下一篇

西达本胺治疗乳腺肿瘤的研究进展 #br#

只向成，曹黎霞，史振东，刘晶晶，张瑾△
  

  1. 天津医科大学肿瘤医院乳腺三科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究
    中心（邮编     300060）

  • 收稿日期:2019-10-31 修回日期:2020-03-16 出版日期:2020-06-15 发布日期:2020-06-15
  • 通讯作者: 张瑾 E-mail:zhangjin@tjmuch.com
  • 基金资助:
    EZH2介导的miR-21激活及miR-200a/b表达沉默协同参与三 阴性乳腺癌恶性进展的机制研究;CENP-U调控乳腺癌发生过程的功能研究

Research progression in the treatment of breast tumors with Chidamide #br#

ZHI Xiang-cheng, CAO Li-xia, SHI Zhen-dong, LIU Jing-jing, ZHANG Jin△ #br#   

  1. Abstract: Chidamide is the first subtype selective histone deacetylase (HDAC) inhibitor independently developed and synthesized in China, belonging to epigenetic drugs.Histone is one of the basic components of human chromosomes, and its acetylation plays an important role in the development of tumors.Studies have shown that when HDAC is overexpressed in cells, it can lead to an acetylation imbalance, which in turn induces tumorigenesis.Therefore, inhibiting the effect of HDAC has become one of the important approaches of tumor therapy.
  • Received:2019-10-31 Revised:2020-03-16 Published:2020-06-15 Online:2020-06-15

PDF (PC)

2313

PDF (Mobile)

16

摘要： 摘要：西达本胺是我国自主研发合成的首个亚型选择性组蛋白脱乙酰化酶抑制剂（HDACi），属于表观遗传学相 关药物。组蛋白是人体内染色体的基本组成单位之一，其乙酰化作用在肿瘤的发生发展中扮演着重要角色。研究 显示，组蛋白脱乙酰化酶（HDAC）在细胞中过量表达时，会导致乙酰化失衡现象，进而诱导肿瘤发生。因此，抑制 HDAC的作用已成为肿瘤治疗的重要途径之一。

关键词: 乳腺肿瘤, 组蛋白脱乙酰基酶抑制剂, 西达本胺, 综述

Abstract: Chidamide is the first subtype selective histone deacetylase (HDAC) inhibitor independently developed and synthesized in China, belonging to epigenetic drugs.Histone is one of the basic components of human chromosomes, and its acetylation plays an important role in the development of tumors.Studies have shown that when HDAC is overexpressed in cells, it can lead to an acetylation imbalance that can lead to tumorigenesis.Therefore, inhibiting the effect of HDAC has become one of the important approaches of tumor therapy.

Key words: breast neoplasms, histone deacetylase inhibitors, Chidamide, review